Arvinas, Inc. - Common Stock (NQ:ARVN)

12.37 +0.34 (+2.83%)

Streaming Delayed Price Updated: 2:23 PM EST, Jan 21, 2026 Add to My Watchlist

Price and Volume

Volume	316,286
Open	11.95
Bid (Size)	12.35 (300)
Ask (Size)	12.39 (100)
Prev. Close	12.03
Today's Range	11.94 - 12.61
52wk Range	5.900 - 20.38
Shares Outstanding	70,800,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

December 06, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

November 26, 2025

From Arvinas Inc.

Via GlobeNewswire

Performance

YTD	+7.8%	+7.8%
1 Month	+0.4%	+0.4%
3 Month	+28.1%	+28.1%
6 Month	+63.2%	+63.2%
1 Year	-33.4%	-33.4%

More News

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

November 24, 2025

From Arvinas Inc.

Via GlobeNewswire

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Top movers in Tuesday's session ↗

November 18, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 18, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 18, 2025

Via Chartmill

Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday ↗

November 18, 2025

Via Benzinga

These stocks that are showing activity before the opening bell on Tuesday. ↗

November 18, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 18, 2025

Via Benzinga

Arvinas Inc (NASDAQ:ARVN) Tops Q3 2025 Earnings Estimates and Provides Pipeline Updates ↗

November 05, 2025

Via Chartmill

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 05, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

November 03, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

October 29, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 24, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 22, 2025

From Arvinas Inc.

Via GlobeNewswire

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

October 20, 2025

From Arvinas Inc.

Via GlobeNewswire

Forecasting The Future: 7 Analyst Projections For Arvinas ↗

October 15, 2025

Via Benzinga

This GE Vernova Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday ↗

October 15, 2025

Via Benzinga

Karooooo Posts Downbeat Earnings, Joins ASP Isotopes And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 15, 2025

Via Benzinga

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

October 13, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

October 05, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

October 01, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

September 17, 2025

From Arvinas Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Arvinas, Inc. - Common Stock publicly traded?

Yes, Arvinas, Inc. - Common Stock is publicly traded.

What exchange does Arvinas, Inc. - Common Stock trade on?

Arvinas, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arvinas, Inc. - Common Stock?

The ticker symbol for Arvinas, Inc. - Common Stock is ARVN on the Nasdaq Stock Market

What is the current price of Arvinas, Inc. - Common Stock?

The current price of Arvinas, Inc. - Common Stock is 12.37

When was Arvinas, Inc. - Common Stock last traded?

The last trade of Arvinas, Inc. - Common Stock was at 01/21/26 02:23 PM ET

What is the market capitalization of Arvinas, Inc. - Common Stock?

The market capitalization of Arvinas, Inc. - Common Stock is 875.80M

How many shares of Arvinas, Inc. - Common Stock are outstanding?

Arvinas, Inc. - Common Stock has 876M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.